<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462357</url>
  </required_header>
  <id_info>
    <org_study_id>115411</org_study_id>
    <nct_id>NCT01462357</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil® Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females</brief_title>
  <official_title>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil® Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix
      administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered
      according to a 2-dose schedule at 0, 6 months or the standard 3-dose schedule of 0, 2, 6
      months in 9-14 years old healthy females.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-HPV-16/18, as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)</measure>
    <time_frame>One month after the last dose of study vaccine (Month 7)</time_frame>
    <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 19 and 18 EL.U/mL, respectively), in the serum of subjects seronegative before vaccination in the primary study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</measure>
    <time_frame>One month after the last dose of study vaccine (Month 7)</time_frame>
    <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean concentrations (GMC) and expressed in ELISA units per milliliter (EL.U/mL) based on ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV-16/18 Seroconversion Rates Assessed by ELISA</measure>
    <time_frame>At Month 36</time_frame>
    <description>Seroconversion was defined as the appearance of antibodies [i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 3.1 and 3.2 international units per milliliter (IU/mL), respectively], in the serum of subjects who were seronegative before vaccination in the primary study.
The assay cut-offs used for analyses at Month 36 were modified to 3.1 and 3.2 IU/mL, after applying the conversion factor from EL.U/mL to IU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</measure>
    <time_frame>At Month 36</time_frame>
    <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean titers (GMT) and expressed in IU/mL.
Assay cut-offs used for analyses at Month 36 were modified to 3.1 and 3.2 IU/mL respectively, after applying the conversion factor from EL.U/mL to IU/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16/18 Seroconversion Rates Assessed by ELISA</measure>
    <time_frame>At Day 0 and Months 12, 18, 24 and 36</time_frame>
    <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 19 and 18 EL.U/mL, respectively) in the serum of subjects seronegative before vaccination in the primary study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</measure>
    <time_frame>At Day 0 and Months 12, 18, 24 and 36</time_frame>
    <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean concentrations (GMC) and expressed in ELISA units per milliliter (EL.U/mL) based on ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16/18 Seroconversion Rates Assessed by Pseudovirion-based Neutralization Assay (PBNA) in a Subset of Subjects</measure>
    <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
    <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to ≥ 40 ED50) in the serum of subjects seronegative before vaccination in the primary study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16/18 Antibody Titers Assessed by PBNA in a Subset of Subjects</measure>
    <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
    <description>Anti-HPV 16/18 antibody titers were presented as geometric mean titers (GMT) and expressed in titers using the PBNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16/18 Seroconversion Rates Assessed by PBNA in a Subset of Subjects</measure>
    <time_frame>At Months 24 and 36</time_frame>
    <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to ≥ 40 ED50) in the serum of subjects seronegative before vaccination in the primary study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16/18 Antibody Titers Assessed by PBNA in a Subset of Subjects</measure>
    <time_frame>At Months 24 and 36</time_frame>
    <description>Anti-HPV 16/18 antibody titers were presented as geometric mean titers (GMT) and expressed in titers using the PBNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell-mediated Immune Responses in the Sub-cohort for CMI</measure>
    <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
    <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-γ), Tumour necrosis factor-alpha (TNF-α) and CD40-ligand (CD40-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell-mediated Immune Responses in the Sub-cohort for CMI</measure>
    <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
    <description>The frequency of B-cell Elispot response to HPV-16/18 by overall status was presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms</measure>
    <time_frame>During the 7-day period (Days 0-6) following vaccination (across doses)</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimetres (mm) of injection site. Relationship analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day period (Days 0-6) following vaccination (across doses)</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, temperature [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)] and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 30-day period (Days 0-29) post-vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Potentially Immune Mediated Diseases (pIMDs)</measure>
    <time_frame>From Day 0 to Month 36 (throughout the study period)</time_frame>
    <description>Note: Results beyond Month 24 will be updated when validated results become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Medically Significant Conditions (MSCs)</measure>
    <time_frame>From Day 0 to Month 36 (throughout the study period)</time_frame>
    <description>MSCs were defined as AEs prompting emergency room (ER) or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs not related to common diseases. Common diseases include: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 0 to Month 36 (throughout the study period)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Starting a Concomitant Medication</measure>
    <time_frame>During the 30-day (Days 0-29) post-vaccination period</time_frame>
    <description>The outcome presents the number of subjects starting any concomitant medication, as well as any antipyretic, any prophylactic antipyretic and any antibiotic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Starting a Concomitant Medication</measure>
    <time_frame>From Day 0 to Month 36 (throughout the study period)</time_frame>
    <description>The outcome presents the number of subjects starting any concomitant medication, as well as any antipyretic, any prophylactic antipyretic and any antibiotic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Completing the Vaccination Schedule</measure>
    <time_frame>Throughout the study period (From Day 0 up to Month 36)</time_frame>
    <description>The number of subjects who have completed the three-dose vaccination schedule in all groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pregnancies</measure>
    <time_frame>Throughout the study period (From Day 0 up to Month 36)</time_frame>
    <description>Note: No pregnancies were reported up to the Month 36 time point.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1079</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix 2 dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gardasil 2 dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gardasil 3 dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix</intervention_name>
    <description>2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6</description>
    <arm_group_label>Cervarix 2 dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gard_2D) or at Day 0, Month 2 and Month 6 (Gard_3D), respectively.</description>
    <arm_group_label>Gardasil 2 dose Group</arm_group_label>
    <arm_group_label>Gardasil 3 dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding</description>
    <arm_group_label>Cervarix 2 dose Group</arm_group_label>
    <arm_group_label>Gardasil 2 dose Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol and subjects who the investigator believes their parent(s)/Legally
             Acceptable Representative(s) (LAR[s]) can and will comply with the requirements of the
             protocol.

          -  A female between, and including, 9 and 14 years of age at the time of the first
             vaccination.

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to
             enrolment in the study. In addition, if capable, the subject should sign and
             personally date a written informed assent.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

               -  has practiced adequate contraception for 30 days prior to vaccination, and

               -  has a negative pregnancy test on the day of vaccination, and

               -  has agreed to continue adequate contraception during the entire treatment period
                  and for two months after completion of the vaccination series.

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  A woman planning to become pregnant, likely to become pregnant (as determined by the
             investigator) or planning to discontinue contraceptive precautions during the
             vaccination phase of the study, i.e. up to two months after the last vaccine dose.

          -  Previous vaccination against HPV or planned administration of another HPV vaccine
             during the study other than those foreseen in the protocol.

          -  Child in care.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine within 30 days preceding the first dose of study vaccine, or planned use
             during the study period (up to Month 36).

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  History of allergic disease, suspected allergy or reactions likely to be exacerbated
             by any component of the study vaccines.

          -  Cancer or autoimmune disease under treatment.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before each dose of vaccine. Administration of routine meningococcal,
             hepatitis B, hepatitis A, inactivated influenza, diphtheria/tetanus and/or
             diphtheria/tetanus-containing vaccine up to 8 days before each dose of study vaccine
             is allowed. Enrolment will be deferred until the subject is outside of specified
             window.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Previous administration of vaccine components.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Family history of congenital or hereditary immunodeficiency.

          -  Major congenital defects or serious chronic illness.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests, which in the opinion of the investigator precludes administration of the study
             vaccine.

          -  Acute disease and/or fever at the time of enrolment.

          -  Drug and/or alcohol abuse.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dax</city>
        <zip>40100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essey les Nancy</city>
        <zip>54270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Havre</city>
        <zip>76620</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosiers d'Egletons</city>
        <zip>19300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Cyr Sur Loir</city>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seysses</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>228510</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>768826</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <zip>SE-631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-701 16</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2011</study_first_posted>
  <results_first_submitted>August 11, 2014</results_first_submitted>
  <results_first_submitted_qc>February 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2016</results_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human papillomavirus</keyword>
  <keyword>Safety</keyword>
  <keyword>HPV vaccine</keyword>
  <keyword>Immune response</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115411</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115411</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115411</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115411</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115411</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115411</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1079 subjects entered this study, of which 4 subjects signed an informed consent but did not receive a single dose of the vaccine and were hence not counted as starting the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix 2 Dose Group</title>
          <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
        <group group_id="P2">
          <title>Gardasil 2 Dose Group</title>
          <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
        <group group_id="P3">
          <title>Gardasil 3 Dose Group</title>
          <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Month 7</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="358"/>
                <participants group_id="P3" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="358"/>
                <participants group_id="P2" count="353"/>
                <participants group_id="P3" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="358"/>
                <participants group_id="P3" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="348"/>
                <participants group_id="P3" count="350"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 18</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="358"/>
                <participants group_id="P3" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="347"/>
                <participants group_id="P3" count="349"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="358"/>
                <participants group_id="P3" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="355"/>
                <participants group_id="P2" count="344"/>
                <participants group_id="P3" count="349"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 36</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
                <participants group_id="P2" count="339"/>
                <participants group_id="P3" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
                <participants group_id="P2" count="339"/>
                <participants group_id="P3" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix 2 Dose Group</title>
          <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
        <group group_id="B2">
          <title>Gardasil 2 Dose Group</title>
          <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
        <group group_id="B3">
          <title>Gardasil 3 Dose Group</title>
          <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="359"/>
            <count group_id="B2" value="358"/>
            <count group_id="B3" value="358"/>
            <count group_id="B4" value="1075"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.5" spread="1.64"/>
                    <measurement group_id="B2" value="11.5" spread="1.56"/>
                    <measurement group_id="B3" value="11.6" spread="1.64"/>
                    <measurement group_id="B4" value="11.53" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="358"/>
                    <measurement group_id="B4" value="1075"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects for Anti-HPV-16/18, as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 19 and 18 EL.U/mL, respectively), in the serum of subjects seronegative before vaccination in the primary study.</description>
        <time_frame>One month after the last dose of study vaccine (Month 7)</time_frame>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Anti-HPV-16/18, as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)</title>
          <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 19 and 18 EL.U/mL, respectively), in the serum of subjects seronegative before vaccination in the primary study.</description>
          <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="334"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 (N=337,334,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                    <measurement group_id="O2" value="334"/>
                    <measurement group_id="O3" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (N=337,334,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                    <measurement group_id="O2" value="334"/>
                    <measurement group_id="O3" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immune response to anti-HPV-16 in terms of SCR:
To evaluate sequentially if the immunogenicity (as determined by ELISA) of Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior to that of Gardasil® vaccine administered according to a 2-dose schedule at 0, 6 months, in 9-14 year-old females, 1 month after the last dose (Month 7).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority with respect to seroconversion will be shown if, at Months 12, 18, 24 and 36, for both anti-HPV-16 and anti-HPV-18 antibodies, the upper limit of the 95% confidence interval (CI) for the difference (Gardasil 2 dose Group - Cervarix 2 dose Group) is below 5%.</non_inferiority_desc>
            <param_type>Difference in SCR</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immune response to anti-HPV-18 in terms of SCR:
To evaluate sequentially if the immunogenicity (as determined by ELISA) of Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior to that of Gardasil® vaccine administered according to a 2-dose schedule at 0, 6 months, in 9-14 year-old females, 1 month after the last dose (Month 7).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority with respect to seroconversion will be shown if, at Months 12, 18, 24 and 36, for both anti-HPV-16 and anti-HPV-18 antibodies, the upper limit of the 95% confidence interval (CI) for the difference (Gardasil 2 dose Group - Cervarix 2 dose Group) is below 5%.</non_inferiority_desc>
            <param_type>Difference in SCR</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</title>
        <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean concentrations (GMC) and expressed in ELISA units per milliliter (EL.U/mL) based on ELISA.</description>
        <time_frame>One month after the last dose of study vaccine (Month 7)</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</title>
          <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean concentrations (GMC) and expressed in ELISA units per milliliter (EL.U/mL) based on ELISA.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="334"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 (N=337,334,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8311.4" lower_limit="7745.8" upper_limit="8918.3"/>
                    <measurement group_id="O2" value="5061" lower_limit="4604.1" upper_limit="5563.3"/>
                    <measurement group_id="O3" value="4864" lower_limit="4481.9" upper_limit="5278.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (N=337,334,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5249.7" lower_limit="4835.4" upper_limit="5699.5"/>
                    <measurement group_id="O2" value="1213" lower_limit="1098.7" upper_limit="1339.1"/>
                    <measurement group_id="O3" value="1654.5" lower_limit="1485.8" upper_limit="1842.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immune response to anti-HPV-16 in terms of GMT:
To evaluate sequentially if the immunogenicity (as determined by ELISA) of Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior to that of Gardasil® vaccine administered according to a 2-dose schedule at 0, 6 months, in 9-14 year-old females, 1 month after the last dose (Month 7).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority with respect to GMT will be shown if, at Months 12, 18, 24 and 36, for both anti-HPV-16 and anti-HPV-18 antibodies, the upper limit of the 95% confidence interval (CI) for the GMT ratio (Gardasil 2 dose Group/Cervarix 2 dose Group) is below 2.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immune response to anti-HPV-18 in terms of GMT:
To evaluate sequentially if the immunogenicity (as determined by ELISA) of Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior to that of Gardasil® vaccine administered according to a 2-dose schedule at 0, 6 months, in 9-14 year-old females, 1 month after the last dose (Month 7).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority with respect to GMT will be shown if, at Months 12, 18, 24 and 36, for both anti-HPV-16 and anti-HPV-18 antibodies, the upper limit of the 95% confidence interval (CI) for the GMT ratio (Gardasil 2 dose Group/Cervarix 2 dose Group) is below 2.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV-18 immune response:
To evaluate sequentially if the immunogenicity (as determined by ELISA) of Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is superior to that of Gardasil® vaccine administered according to a 2-dose schedule at 0, 6 months, in 9-14 year-old females, 1 month after the last dose (Month 7).
Superiority will be shown if the lower limit of the 95% CI for the ratio of GMTs (Cervarix 2 dose Group divided by Gardasil 2 dose Group) is above 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>4.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.97</ci_lower_limit>
            <ci_upper_limit>5.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV-16 immune response:
To evaluate sequentially if the immunogenicity (as determined by ELISA) of Cervarix™ vaccine administered according to a 2-dose schedule at 0, 6 months is superior to that of Gardasil® vaccine administered according to a 2-dose schedule at 0, 6 months, in 9-14 year-old females, 1 month after the last dose (Month 7).
Superiority will be shown if the lower limit of the 95% CI for the ratio of GMTs (Cervarix 2 dose Group divided by Gardasil 2 dose Group) is above 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.49</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV-16/18 Seroconversion Rates Assessed by ELISA</title>
        <description>Seroconversion was defined as the appearance of antibodies [i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 3.1 and 3.2 international units per milliliter (IU/mL), respectively], in the serum of subjects who were seronegative before vaccination in the primary study.
The assay cut-offs used for analyses at Month 36 were modified to 3.1 and 3.2 IU/mL, after applying the conversion factor from EL.U/mL to IU/mL.</description>
        <time_frame>At Month 36</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Seroconversion Rates Assessed by ELISA</title>
          <description>Seroconversion was defined as the appearance of antibodies [i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 3.1 and 3.2 international units per milliliter (IU/mL), respectively], in the serum of subjects who were seronegative before vaccination in the primary study.
The assay cut-offs used for analyses at Month 36 were modified to 3.1 and 3.2 IU/mL, after applying the conversion factor from EL.U/mL to IU/mL.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="313"/>
                <count group_id="O3" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, Month 36 (N=324,313,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 36 (N=324,313,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="270"/>
                    <measurement group_id="O3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</title>
        <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean titers (GMT) and expressed in IU/mL.
Assay cut-offs used for analyses at Month 36 were modified to 3.1 and 3.2 IU/mL respectively, after applying the conversion factor from EL.U/mL to IU/mL.</description>
        <time_frame>At Month 36</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</title>
          <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean titers (GMT) and expressed in IU/mL.
Assay cut-offs used for analyses at Month 36 were modified to 3.1 and 3.2 IU/mL respectively, after applying the conversion factor from EL.U/mL to IU/mL.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="313"/>
                <count group_id="O3" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, Month 36 (N=324,313,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.2" lower_limit="160.6" upper_limit="191.2"/>
                    <measurement group_id="O2" value="61.6" lower_limit="54.1" upper_limit="70.1"/>
                    <measurement group_id="O3" value="77.8" lower_limit="70.2" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 36 (N=324,313,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="77.0" upper_limit="95.0"/>
                    <measurement group_id="O2" value="12.5" lower_limit="11.0" upper_limit="14.3"/>
                    <measurement group_id="O3" value="21.1" lower_limit="18.3" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16/18 Seroconversion Rates Assessed by ELISA</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 19 and 18 EL.U/mL, respectively) in the serum of subjects seronegative before vaccination in the primary study.</description>
        <time_frame>At Day 0 and Months 12, 18, 24 and 36</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Seroconversion Rates Assessed by ELISA</title>
          <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to 19 and 18 EL.U/mL, respectively) in the serum of subjects seronegative before vaccination in the primary study.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="334"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, Day 0 (N=337,334,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Day 0 (N=337,334,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 12 (N=331,325,327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="325"/>
                    <measurement group_id="O3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 12 (N=331,325,327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="324"/>
                    <measurement group_id="O3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 18 (N=329,327,330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                    <measurement group_id="O2" value="326"/>
                    <measurement group_id="O3" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 18 (N=329,327,330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 24 (N=324,320,324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="319"/>
                    <measurement group_id="O3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 24 (N=324,320,324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="298"/>
                    <measurement group_id="O3" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 36 (N=324,313,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 36 (N=324,313,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="270"/>
                    <measurement group_id="O3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</title>
        <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean concentrations (GMC) and expressed in ELISA units per milliliter (EL.U/mL) based on ELISA.</description>
        <time_frame>At Day 0 and Months 12, 18, 24 and 36</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Antibody Concentrations Assessed by ELISA</title>
          <description>Anti-HPV 16/18 antibody concentrations were presented as geometric mean concentrations (GMC) and expressed in ELISA units per milliliter (EL.U/mL) based on ELISA.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="334"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, Day 0 (N=337,334,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="9.5" upper_limit="10.2"/>
                    <measurement group_id="O2" value="9.8" lower_limit="9.5" upper_limit="10.1"/>
                    <measurement group_id="O3" value="10.0" lower_limit="9.7" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Day 0 (N=337,334,334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="9.0" upper_limit="9.2"/>
                    <measurement group_id="O2" value="9.1" lower_limit="9.0" upper_limit="9.2"/>
                    <measurement group_id="O3" value="9" lower_limit="9.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 12 (N=331,325,327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2247.9" lower_limit="2052.2" upper_limit="2462.2"/>
                    <measurement group_id="O2" value="1283.9" lower_limit="1152.1" upper_limit="1430.8"/>
                    <measurement group_id="O3" value="1610.5" lower_limit="1468.9" upper_limit="1765.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 12 (N=331,325,327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1311.4" lower_limit="1187.3" upper_limit="1448.4"/>
                    <measurement group_id="O2" value="266.0" lower_limit="236.2" upper_limit="299.4"/>
                    <measurement group_id="O3" value="477.8" lower_limit="422.7" upper_limit="540.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 18 (N=329,327,330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1516.2" lower_limit="1393.4" upper_limit="1649.8"/>
                    <measurement group_id="O2" value="675.8" lower_limit="600" upper_limit="761.1"/>
                    <measurement group_id="O3" value="828" lower_limit="749.8" upper_limit="914.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 18 (N=329,327,330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="763.1" lower_limit="691.3" upper_limit="842.5"/>
                    <measurement group_id="O2" value="133.8" lower_limit="117.6" upper_limit="152.1"/>
                    <measurement group_id="O3" value="230.8" lower_limit="202.1" upper_limit="263.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 24 (N=324,320,324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1317.5" lower_limit="1213.9" upper_limit="1430"/>
                    <measurement group_id="O2" value="514.4" lower_limit="456.9" upper_limit="579.2"/>
                    <measurement group_id="O3" value="639.9" lower_limit="579.6" upper_limit="706.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 24 (N=324,317,324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628.6" lower_limit="569.4" upper_limit="694"/>
                    <measurement group_id="O2" value="107.8" lower_limit="94.8" upper_limit="122.6"/>
                    <measurement group_id="O3" value="182.2" lower_limit="159.6" upper_limit="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 36 (N=324,313,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1068.9" lower_limit="979.6" upper_limit="1166.5"/>
                    <measurement group_id="O2" value="375.4" lower_limit="329.6" upper_limit="427.5"/>
                    <measurement group_id="O3" value="475.3" lower_limit="428.7" upper_limit="527.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 36 (N=324,313,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487.8" lower_limit="439.3" upper_limit="541.8"/>
                    <measurement group_id="O2" value="71.3" lower_limit="62.3" upper_limit="81.5"/>
                    <measurement group_id="O3" value="120.2" lower_limit="104.3" upper_limit="138.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16/18 Seroconversion Rates Assessed by Pseudovirion-based Neutralization Assay (PBNA) in a Subset of Subjects</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to ≥ 40 ED50) in the serum of subjects seronegative before vaccination in the primary study.</description>
        <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Seroconversion Rates Assessed by Pseudovirion-based Neutralization Assay (PBNA) in a Subset of Subjects</title>
          <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to ≥ 40 ED50) in the serum of subjects seronegative before vaccination in the primary study.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, Day 0 (N=92,95,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Day 0 (N=92,95,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 7 (N=92,95,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 7 (N=92,95,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 12 (N=90,93,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 12 (N=90,93,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 18 (N=90,92,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 18 (N=89,92,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 24 (N=88,88,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 24 (N=88,86,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 36 (N=89,87,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 36 (N=89,87,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16/18 Antibody Titers Assessed by PBNA in a Subset of Subjects</title>
        <description>Anti-HPV 16/18 antibody titers were presented as geometric mean titers (GMT) and expressed in titers using the PBNA.</description>
        <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Antibody Titers Assessed by PBNA in a Subset of Subjects</title>
          <description>Anti-HPV 16/18 antibody titers were presented as geometric mean titers (GMT) and expressed in titers using the PBNA.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, Day 0 (N=92,95,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="20.2" lower_limit="19.8" upper_limit="20.5"/>
                    <measurement group_id="O3" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Day 0 (N=92,95,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 7 (N=92,95,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51043.8" lower_limit="42657.9" upper_limit="61078.3"/>
                    <measurement group_id="O2" value="19119.4" lower_limit="15249" upper_limit="23972.1"/>
                    <measurement group_id="O3" value="21377.9" lower_limit="16900.1" upper_limit="27042.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 7 (N=92,95,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23228" lower_limit="18677" upper_limit="28887.8"/>
                    <measurement group_id="O2" value="4709.9" lower_limit="3604.2" upper_limit="6154.9"/>
                    <measurement group_id="O3" value="8009.4" lower_limit="6111.1" upper_limit="10497.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 12 (N=90,93,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10635.3" lower_limit="8555.9" upper_limit="13220.0"/>
                    <measurement group_id="O2" value="3959.4" lower_limit="3039.1" upper_limit="5158.4"/>
                    <measurement group_id="O3" value="5858.1" lower_limit="4610.9" upper_limit="7442.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 12 (N=90,93,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3651.5" lower_limit="2903.6" upper_limit="4592.1"/>
                    <measurement group_id="O2" value="656.3" lower_limit="493.6" upper_limit="872.6"/>
                    <measurement group_id="O3" value="1734.2" lower_limit="1268.4" upper_limit="2371.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 18 (N=90,92,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8388.4" lower_limit="6647.7" upper_limit="10584.9"/>
                    <measurement group_id="O2" value="1953.5" lower_limit="1386.6" upper_limit="2752.3"/>
                    <measurement group_id="O3" value="2988.9" lower_limit="2227.2" upper_limit="4011.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 18 (N=89,92,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2381.1" lower_limit="1858.7" upper_limit="3050.2"/>
                    <measurement group_id="O2" value="283.1" lower_limit="209.4" upper_limit="382.7"/>
                    <measurement group_id="O3" value="805.7" lower_limit="574.4" upper_limit="1130.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 24 (N=88,88,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5059.5" lower_limit="4112.2" upper_limit="6225.1"/>
                    <measurement group_id="O2" value="1138.1" lower_limit="845.5" upper_limit="1531.9"/>
                    <measurement group_id="O3" value="1965.5" lower_limit="1510.6" upper_limit="2557.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 24 (N=88,86,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1725.1" lower_limit="1359.3" upper_limit="2189.4"/>
                    <measurement group_id="O2" value="234.6" lower_limit="175.8" upper_limit="313.2"/>
                    <measurement group_id="O3" value="568.0" lower_limit="419.0" upper_limit="770.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 36 (N=89,87,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4357.8" lower_limit="3577.8" upper_limit="5307.9"/>
                    <measurement group_id="O2" value="1071.7" lower_limit="811.2" upper_limit="1415.7"/>
                    <measurement group_id="O3" value="1577.0" lower_limit="1210.4" upper_limit="2054.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 36 (N=89,87,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1613.9" lower_limit="1267.6" upper_limit="2054.7"/>
                    <measurement group_id="O2" value="185.8" lower_limit="140.4" upper_limit="245.8"/>
                    <measurement group_id="O3" value="472.8" lower_limit="345.8" upper_limit="646.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16/18 Seroconversion Rates Assessed by PBNA in a Subset of Subjects</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to ≥ 40 ED50) in the serum of subjects seronegative before vaccination in the primary study.</description>
        <time_frame>At Months 24 and 36</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Seroconversion Rates Assessed by PBNA in a Subset of Subjects</title>
          <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers greater than or equal to ≥ 40 ED50) in the serum of subjects seronegative before vaccination in the primary study.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, Month 24 (N=96,91,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 24 (N=96,89,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 36 (N=98,92,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 36 (N=97,92,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16/18 Antibody Titers Assessed by PBNA in a Subset of Subjects</title>
        <description>Anti-HPV 16/18 antibody titers were presented as geometric mean titers (GMT) and expressed in titers using the PBNA.</description>
        <time_frame>At Months 24 and 36</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16/18 Antibody Titers Assessed by PBNA in a Subset of Subjects</title>
          <description>Anti-HPV 16/18 antibody titers were presented as geometric mean titers (GMT) and expressed in titers using the PBNA.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, Month 24 (N=96,91,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4609.1" lower_limit="3673.5" upper_limit="5782.9"/>
                    <measurement group_id="O2" value="1133.9" lower_limit="848.1" upper_limit="1516.0"/>
                    <measurement group_id="O3" value="1948.1" lower_limit="1515.0" upper_limit="2505.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 24 (N=96,89,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1638.6" lower_limit="1297.9" upper_limit="2068.8"/>
                    <measurement group_id="O2" value="237.2" lower_limit="179.1" upper_limit="314.3"/>
                    <measurement group_id="O3" value="573.0" lower_limit="425.0" upper_limit="772.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, Month 36 (N=98,92,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4011.7" lower_limit="3229.7" upper_limit="4983.0"/>
                    <measurement group_id="O2" value="1058.4" lower_limit="806.3" upper_limit="1389.2"/>
                    <measurement group_id="O3" value="1517.2" lower_limit="1174.7" upper_limit="1959.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, Month 36 (N=97,92,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1513.7" lower_limit="1197.5" upper_limit="1913.2"/>
                    <measurement group_id="O2" value="185.8" lower_limit="142.2" upper_limit="242.7"/>
                    <measurement group_id="O3" value="468.6" lower_limit="346.3" upper_limit="634.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-cell-mediated Immune Responses in the Sub-cohort for CMI</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-γ), Tumour necrosis factor-alpha (TNF-α) and CD40-ligand (CD40-L).</description>
        <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>T-cell-mediated Immune Responses in the Sub-cohort for CMI</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-γ), Tumour necrosis factor-alpha (TNF-α) and CD40-ligand (CD40-L).</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>T-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+ All doubles, Anti-HPV-16, Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="1" upper_limit="97"/>
                    <measurement group_id="O2" value="22" lower_limit="1" upper_limit="73"/>
                    <measurement group_id="O3" value="33" lower_limit="1" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-18, Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="1" upper_limit="83"/>
                    <measurement group_id="O2" value="19" lower_limit="1" upper_limit="101"/>
                    <measurement group_id="O3" value="24" lower_limit="1" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-16, Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1604.5" lower_limit="634.5" upper_limit="3253.5"/>
                    <measurement group_id="O2" value="853" lower_limit="429" upper_limit="1324"/>
                    <measurement group_id="O3" value="1131" lower_limit="694" upper_limit="1969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-18, Month 7(N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="897" lower_limit="522" upper_limit="2497"/>
                    <measurement group_id="O2" value="459" lower_limit="240" upper_limit="761"/>
                    <measurement group_id="O3" value="654.5" lower_limit="384" upper_limit="1284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-16, Month12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1121" lower_limit="659" upper_limit="2340"/>
                    <measurement group_id="O2" value="622.5" lower_limit="316" upper_limit="1261"/>
                    <measurement group_id="O3" value="844.5" lower_limit="546" upper_limit="1652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-18, Month12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="789" lower_limit="400" upper_limit="1492"/>
                    <measurement group_id="O2" value="355" lower_limit="209" upper_limit="673.5"/>
                    <measurement group_id="O3" value="465.5" lower_limit="205" upper_limit="901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-16,Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="1" upper_limit="78"/>
                    <measurement group_id="O2" value="14" lower_limit="1" upper_limit="73"/>
                    <measurement group_id="O3" value="30" lower_limit="1" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-18,Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="1" upper_limit="83"/>
                    <measurement group_id="O2" value="27" lower_limit="1" upper_limit="101"/>
                    <measurement group_id="O3" value="25.5" lower_limit="1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-16,Month 7(N=68,63.65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1507.5" lower_limit="631.5" upper_limit="3043"/>
                    <measurement group_id="O2" value="779" lower_limit="426" upper_limit="1219"/>
                    <measurement group_id="O3" value="1054" lower_limit="670" upper_limit="1938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-18,Month7 (N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="866" lower_limit="509" upper_limit="2379"/>
                    <measurement group_id="O2" value="418" lower_limit="227" upper_limit="775"/>
                    <measurement group_id="O3" value="616.5" lower_limit="344" upper_limit="1193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="990" lower_limit="594" upper_limit="2236"/>
                    <measurement group_id="O2" value="592.5" lower_limit="280" upper_limit="1135"/>
                    <measurement group_id="O3" value="805" lower_limit="469" upper_limit="1545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-18,Month 12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="688" lower_limit="346" upper_limit="1435"/>
                    <measurement group_id="O2" value="340.5" lower_limit="168" upper_limit="604.5"/>
                    <measurement group_id="O3" value="404" lower_limit="219" upper_limit="737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d- IFNγ, Anti-HPV-16,Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="30"/>
                    <measurement group_id="O2" value="14" lower_limit="1" upper_limit="42"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d- IFNγ, Anti-HPV-18,Day 0(N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="1" upper_limit="32"/>
                    <measurement group_id="O2" value="7" lower_limit="1" upper_limit="35"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d- IFNγ, Anti-HPV-16,Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351" lower_limit="164.5" upper_limit="829"/>
                    <measurement group_id="O2" value="314" lower_limit="141" upper_limit="602"/>
                    <measurement group_id="O3" value="398" lower_limit="193" upper_limit="708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d- IFNγ, Anti-HPV-18,Month 7(N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="108" upper_limit="631"/>
                    <measurement group_id="O2" value="127" lower_limit="70" upper_limit="247"/>
                    <measurement group_id="O3" value="181.5" lower_limit="70" upper_limit="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d- IFNγ, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326" lower_limit="110" upper_limit="688"/>
                    <measurement group_id="O2" value="241.5" lower_limit="86" upper_limit="606"/>
                    <measurement group_id="O3" value="337" lower_limit="135" upper_limit="734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d- IFNγ, Anti-HPV-18,Month 12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" lower_limit="87" upper_limit="444"/>
                    <measurement group_id="O2" value="114" lower_limit="56.5" upper_limit="259.5"/>
                    <measurement group_id="O3" value="155.5" lower_limit="56" upper_limit="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-16,Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="1" upper_limit="71"/>
                    <measurement group_id="O2" value="24" lower_limit="1" upper_limit="68"/>
                    <measurement group_id="O3" value="33" lower_limit="1" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-18, Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="42"/>
                    <measurement group_id="O2" value="30" lower_limit="1" upper_limit="66"/>
                    <measurement group_id="O3" value="20" lower_limit="1" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-16,Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1323" lower_limit="537" upper_limit="2702.5"/>
                    <measurement group_id="O2" value="710" lower_limit="368" upper_limit="1058"/>
                    <measurement group_id="O3" value="875" lower_limit="580" upper_limit="1431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-18,Month 7(N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="737" lower_limit="420" upper_limit="2185"/>
                    <measurement group_id="O2" value="321" lower_limit="206" upper_limit="573"/>
                    <measurement group_id="O3" value="503" lower_limit="295" upper_limit="869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="922" lower_limit="528" upper_limit="2050"/>
                    <measurement group_id="O2" value="487.5" lower_limit="285" upper_limit="991"/>
                    <measurement group_id="O3" value="702.5" lower_limit="450" upper_limit="1379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-18,Month 12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="620" lower_limit="311" upper_limit="1157"/>
                    <measurement group_id="O2" value="274" lower_limit="164.5" upper_limit="550.5"/>
                    <measurement group_id="O3" value="380" lower_limit="160" upper_limit="705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-16,Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="1" upper_limit="52"/>
                    <measurement group_id="O2" value="32" lower_limit="1" upper_limit="73"/>
                    <measurement group_id="O3" value="16" lower_limit="1" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-18,Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="1" upper_limit="73"/>
                    <measurement group_id="O2" value="19" lower_limit="1" upper_limit="82"/>
                    <measurement group_id="O3" value="21" lower_limit="1" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-16,Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1103" lower_limit="432" upper_limit="2399"/>
                    <measurement group_id="O2" value="605" lower_limit="276" upper_limit="919"/>
                    <measurement group_id="O3" value="804" lower_limit="458" upper_limit="1512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-18,Month 7(N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647" lower_limit="371" upper_limit="1765"/>
                    <measurement group_id="O2" value="319" lower_limit="153" upper_limit="594"/>
                    <measurement group_id="O3" value="517" lower_limit="272" upper_limit="978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="884" lower_limit="488" upper_limit="1924"/>
                    <measurement group_id="O2" value="527" lower_limit="210" upper_limit="1033"/>
                    <measurement group_id="O3" value="725" lower_limit="383" upper_limit="1445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-18,Month 12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="674" lower_limit="290" upper_limit="1272"/>
                    <measurement group_id="O2" value="299" lower_limit="144.5" upper_limit="600"/>
                    <measurement group_id="O3" value="403" lower_limit="175" upper_limit="771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All Doubles, Anti-HPV-16, Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="14"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="43"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All Doubles, Anti-HPV-18, Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="29"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All Doubles, Anti-HPV-16,Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="33"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="40"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All Doubles, Anti-HPV-18,Month 7(N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="19"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="37"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All Doubles, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="31"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="44"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All Doubles, Anti-HPV-18,Month 12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="27"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="32.5"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-16, Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-18, Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-16,Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="28"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-18,Month 7(N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="24"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-18,Month 12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-16, Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="36"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-18, Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="24"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-16,Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="31"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="36"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-18,Month 7(N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="27"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="28"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="29"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-18, Month 12 (N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="26"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="32.5"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-16, Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-18,Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-16,Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-18,Month 7(N=67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-18,Month 12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-16, Day 0 (N=57,47,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="36"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-18, Day 0 (N=57,46,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="25"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="30"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-16,Month 7(N=68,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="26"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="25"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-18,Month 7(N67,63,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-16,Month 12(N=71,66,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="25"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-18,Month 12(N=71,68,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="21.5"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1097" lower_limit="489" upper_limit="2410"/>
                    <measurement group_id="O2" value="738" lower_limit="360" upper_limit="1109"/>
                    <measurement group_id="O3" value="974" lower_limit="573" upper_limit="1838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630" lower_limit="301" upper_limit="1383"/>
                    <measurement group_id="O2" value="348" lower_limit="202" upper_limit="549"/>
                    <measurement group_id="O3" value="561.5" lower_limit="258" upper_limit="972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1083" lower_limit="510" upper_limit="2269"/>
                    <measurement group_id="O2" value="734" lower_limit="346" upper_limit="1084"/>
                    <measurement group_id="O3" value="964" lower_limit="582" upper_limit="1802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587" lower_limit="282" upper_limit="1344"/>
                    <measurement group_id="O2" value="333" lower_limit="206" upper_limit="534"/>
                    <measurement group_id="O3" value="563.5" lower_limit="289" upper_limit="940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d- IFNγ, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276" lower_limit="111" upper_limit="781"/>
                    <measurement group_id="O2" value="315" lower_limit="128" upper_limit="519"/>
                    <measurement group_id="O3" value="431" lower_limit="157" upper_limit="777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d- IFNγ, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="59" upper_limit="440"/>
                    <measurement group_id="O2" value="106" lower_limit="51" upper_limit="227"/>
                    <measurement group_id="O3" value="218" lower_limit="63" upper_limit="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="879.5" lower_limit="429" upper_limit="1711"/>
                    <measurement group_id="O2" value="574" lower_limit="280" upper_limit="898"/>
                    <measurement group_id="O3" value="687" lower_limit="479" upper_limit="1480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494" lower_limit="238" upper_limit="926"/>
                    <measurement group_id="O2" value="248" lower_limit="138" upper_limit="415"/>
                    <measurement group_id="O3" value="400.5" lower_limit="206" upper_limit="713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="755" lower_limit="375" upper_limit="1668"/>
                    <measurement group_id="O2" value="524" lower_limit="235" upper_limit="876"/>
                    <measurement group_id="O3" value="791" lower_limit="416" upper_limit="1516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="479" lower_limit="183" upper_limit="1036"/>
                    <measurement group_id="O2" value="238" lower_limit="130" upper_limit="478"/>
                    <measurement group_id="O3" value="519" lower_limit="228" upper_limit="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All Doubles, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="29"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All Doubles, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="30"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="30"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="23"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="19"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="23"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-16,Month 24(N=66,65,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="27"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-18,Month 24(N=65,65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="18"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="23"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1012.0" lower_limit="427.0" upper_limit="2373.0"/>
                    <measurement group_id="O2" value="685.0" lower_limit="385.0" upper_limit="1321.0"/>
                    <measurement group_id="O3" value="842.5" lower_limit="437.5" upper_limit="1624.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ All doubles, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="682.0" lower_limit="313.0" upper_limit="1425.0"/>
                    <measurement group_id="O2" value="350.0" lower_limit="196.0" upper_limit="665.0"/>
                    <measurement group_id="O3" value="516.0" lower_limit="270.0" upper_limit="1029.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="957.0" lower_limit="465.0" upper_limit="2303.0"/>
                    <measurement group_id="O2" value="685.0" lower_limit="349.0" upper_limit="1321.0"/>
                    <measurement group_id="O3" value="778.5" lower_limit="416.5" upper_limit="1560.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-CD40L, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="671.0" lower_limit="290.0" upper_limit="1435.0"/>
                    <measurement group_id="O2" value="337.0" lower_limit="204.0" upper_limit="648.0"/>
                    <measurement group_id="O3" value="499.0" lower_limit="264.0" upper_limit="1020.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IFNγ, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.5" lower_limit="81.0" upper_limit="667.0"/>
                    <measurement group_id="O2" value="301.0" lower_limit="134.0" upper_limit="571.0"/>
                    <measurement group_id="O3" value="270.5" lower_limit="129.0" upper_limit="666.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IFNγ, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.0" lower_limit="51.0" upper_limit="376.0"/>
                    <measurement group_id="O2" value="109.0" lower_limit="27.0" upper_limit="230.0"/>
                    <measurement group_id="O3" value="155.0" lower_limit="45.0" upper_limit="314.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="784.0" lower_limit="331.0" upper_limit="1673.0"/>
                    <measurement group_id="O2" value="517.0" lower_limit="295.0" upper_limit="1014.0"/>
                    <measurement group_id="O3" value="680.0" lower_limit="308.0" upper_limit="1245.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-IL-2, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507.0" lower_limit="213.0" upper_limit="1069.0"/>
                    <measurement group_id="O2" value="274.0" lower_limit="137.0" upper_limit="467.0"/>
                    <measurement group_id="O3" value="341.0" lower_limit="168.0" upper_limit="798.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="786.5" lower_limit="343.0" upper_limit="1930.0"/>
                    <measurement group_id="O2" value="547.0" lower_limit="282.0" upper_limit="1005.0"/>
                    <measurement group_id="O3" value="724.5" lower_limit="368.0" upper_limit="1338.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-d-TNFα, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588.0" lower_limit="250.0" upper_limit="1138.0"/>
                    <measurement group_id="O2" value="301.0" lower_limit="120.0" upper_limit="453.0"/>
                    <measurement group_id="O3" value="479.0" lower_limit="200.0" upper_limit="808.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All doubles, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="48.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="28.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-All doubles, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="41.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="24.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-CD40L, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="47.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IFNγ, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="40.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-IL-2, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-16,Month 36(N=58,55,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-d-TNFα, Anti-HPV-18,Month 36(N=57,55,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="21.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>B-cell-mediated Immune Responses in the Sub-cohort for CMI</title>
        <description>The frequency of B-cell Elispot response to HPV-16/18 by overall status was presented.</description>
        <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>B-cell-mediated Immune Responses in the Sub-cohort for CMI</title>
          <description>The frequency of B-cell Elispot response to HPV-16/18 by overall status was presented.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available at the time of the analysis.</population>
          <units>B-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16, PRE (N=74,59,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, PRE (N=74,59,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, Month 7 (N=76,72,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1605.5" lower_limit="593.5" upper_limit="3483.5"/>
                    <measurement group_id="O2" value="1097.5" lower_limit="449" upper_limit="2068"/>
                    <measurement group_id="O3" value="687" lower_limit="115.5" upper_limit="1966.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, Month 7 (N=76,72,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="593.5" lower_limit="103.5" upper_limit="1771"/>
                    <measurement group_id="O2" value="80" lower_limit="0" upper_limit="376"/>
                    <measurement group_id="O3" value="111" lower_limit="0" upper_limit="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, Month 12 (N=56,56,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396.5" lower_limit="89" upper_limit="1044"/>
                    <measurement group_id="O2" value="248" lower_limit="61.5" upper_limit="756"/>
                    <measurement group_id="O3" value="281" lower_limit="47" upper_limit="974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, Month 12 (N=56,56,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252" lower_limit="77" upper_limit="635"/>
                    <measurement group_id="O2" value="67" lower_limit="0" upper_limit="182.5"/>
                    <measurement group_id="O3" value="65" lower_limit="0" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, Month 24 (N=52,50,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.5" lower_limit="13" upper_limit="706"/>
                    <measurement group_id="O2" value="204" lower_limit="16" upper_limit="578"/>
                    <measurement group_id="O3" value="256" lower_limit="68" upper_limit="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, Month 24 (N=52,50,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.5" lower_limit="31" upper_limit="370.5"/>
                    <measurement group_id="O2" value="45" lower_limit="0" upper_limit="143"/>
                    <measurement group_id="O3" value="110" lower_limit="0" upper_limit="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, Month 36 (N=59,54,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353.0" lower_limit="91.0" upper_limit="927.0"/>
                    <measurement group_id="O2" value="382.5" lower_limit="166.0" upper_limit="614.0"/>
                    <measurement group_id="O3" value="246.0" lower_limit="21.0" upper_limit="565.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, Month 36 (N=59,54,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.0" lower_limit="1.0" upper_limit="329.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="1.0" upper_limit="228.0"/>
                    <measurement group_id="O3" value="63.0" lower_limit="1.0" upper_limit="150.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimetres (mm) of injection site. Relationship analysis was not performed.</description>
        <time_frame>During the 7-day period (Days 0-6) following vaccination (across doses)</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimetres (mm) of injection site. Relationship analysis was not performed.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                    <measurement group_id="O2" value="276"/>
                    <measurement group_id="O3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, temperature [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)] and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 7-day period (Days 0-6) following vaccination (across doses)</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, temperature [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)] and urticaria. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="199"/>
                    <measurement group_id="O3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Mylagia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 30-day period (Days 0-29) post-vaccination</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Potentially Immune Mediated Diseases (pIMDs)</title>
        <description>Note: Results beyond Month 24 will be updated when validated results become available.</description>
        <time_frame>From Day 0 to Month 36 (throughout the study period)</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Potentially Immune Mediated Diseases (pIMDs)</title>
          <description>Note: Results beyond Month 24 will be updated when validated results become available.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any pIMD(s), Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any pIMD(s), Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any pIMD(s), Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any pIMD(s), Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Medically Significant Conditions (MSCs)</title>
        <description>MSCs were defined as AEs prompting emergency room (ER) or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs not related to common diseases. Common diseases include: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>From Day 0 to Month 36 (throughout the study period)</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Medically Significant Conditions (MSCs)</title>
          <description>MSCs were defined as AEs prompting emergency room (ER) or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs not related to common diseases. Common diseases include: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any MSC(s), Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any MSC(s), Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any MSC(s), Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any MSC(s), Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any MSC(s), Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Day 0 to Month 36 (throughout the study period)</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Starting a Concomitant Medication</title>
        <description>The outcome presents the number of subjects starting any concomitant medication, as well as any antipyretic, any prophylactic antipyretic and any antibiotic.</description>
        <time_frame>During the 30-day (Days 0-29) post-vaccination period</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Starting a Concomitant Medication</title>
          <description>The outcome presents the number of subjects starting any concomitant medication, as well as any antipyretic, any prophylactic antipyretic and any antibiotic.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any concomitant medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antipyretic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic antipyretic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Starting a Concomitant Medication</title>
        <description>The outcome presents the number of subjects starting any concomitant medication, as well as any antipyretic, any prophylactic antipyretic and any antibiotic.</description>
        <time_frame>From Day 0 to Month 36 (throughout the study period)</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Starting a Concomitant Medication</title>
          <description>The outcome presents the number of subjects starting any concomitant medication, as well as any antipyretic, any prophylactic antipyretic and any antibiotic.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any antipyretic, M7 [N=359,358,354]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any concomitant medication, M7 [N=359,358,354]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antibiotic, M7 [N=359,358,354]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any concomitant medication, M12 [N=356,348,350]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antipyretic, M12 [N=356,348,350]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antibiotic, M12 [N=356,348,350]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any concomitant medication, M18 [N=356,347,349]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antipyretic, M18 [N=356,347,349]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antibiotic, M18 [N=356,347,349]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic antipyretic, M12 [N=356,348,350]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic antipyretic, M18 [N=356,347,349]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any concomitant medication, M24 [N=355,344,349]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antipyretic, M24 [N=355,344,349]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic antipyretic, M24 [N=356,347,349]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antibiotic, M24 [N=355,344,349]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any concomitant medication, M36 [N=351,339,346]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antipyretic, M36 [N=351,339,346]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic antipyretic, M36 [N=351,339,346]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any antibiotic, M36 [N=351,339,346]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic antibiotic, M36 [N=351,339,346]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Completing the Vaccination Schedule</title>
        <description>The number of subjects who have completed the three-dose vaccination schedule in all groups.</description>
        <time_frame>Throughout the study period (From Day 0 up to Month 36)</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Completing the Vaccination Schedule</title>
          <description>The number of subjects who have completed the three-dose vaccination schedule in all groups.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administered, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357"/>
                    <measurement group_id="O2" value="352"/>
                    <measurement group_id="O3" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pregnancies</title>
        <description>Note: No pregnancies were reported up to the Month 36 time point.</description>
        <time_frame>Throughout the study period (From Day 0 up to Month 36)</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 2 Dose Group</title>
            <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil 2 Dose Group</title>
            <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Gardasil 3 Dose Group</title>
            <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Pregnancies</title>
          <description>Note: No pregnancies were reported up to the Month 36 time point.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any pregnancy, M12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any pregnancy, M18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any pregnancy, M24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any pregnancy, M36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms: up to Day 7 post vaccination. AEs: up to Day 30 post vaccination. SAEs throughout the study period (up to Month 36).</time_frame>
      <desc>For the systematically assessed other (non-serious) adverse events, the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix 2 Dose Group</title>
          <description>Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
        <group group_id="E2">
          <title>Gardasil 2 Dose Group</title>
          <description>Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
        <group group_id="E3">
          <title>Gardasil 3 Dose Group</title>
          <description>Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Mouth cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vulval ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="329" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="276" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="295" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="329" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="276" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="295" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="193" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastrointesinal</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="136" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Temperature</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="358"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

